<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03658343</url>
  </required_header>
  <id_info>
    <org_study_id>201807711</org_study_id>
    <secondary_id>5P30CA086862</secondary_id>
    <nct_id>NCT03658343</nct_id>
  </id_info>
  <brief_title>T2* MRI Analysis for Sarcoma</brief_title>
  <official_title>An Exploratory, Pilot Study Evaluating T2* Imaging for Adult Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bryan Allen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Holden Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      T2* imaging is a method to identify labile iron pools in tumor cells. These iron pools may be
      linked to better treatment outcomes for specific types of therapy. This is a small pilot
      study to see if radiation therapy changes the amount of iron in a sarcoma tumor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ferric iron levels detected by T2* MRI</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Change from baseline in Fe3+ iron levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ferrous iron levels detected by T2* MRI</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change from baseline in Fe2+ iron levels</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Radiotherapy</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>T2* Imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo T2* MRI imaging before beginning their course of radiation therapy and then after completing radiation therapy, about 2 weeks before their surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>T2* Imaging</intervention_name>
    <description>T2* imaging sequences for MRI</description>
    <arm_group_label>T2* Imaging</arm_group_label>
    <other_name>magnetic resonance imaging</other_name>
    <other_name>T2-star</other_name>
    <other_name>T2* MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathologically confirmed Sarcoma, by biopsy or excision

          -  prescribed radiation therapy as per standard of care

          -  treatment to begin within 5 weeks after surgery or biopsy

          -  ECOG 0, 1, or 2

          -  ability and willingness to provide informed consent

        Exclusion Criteria:

          -  &lt; 18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan Allen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bryan G. Allen, MD, PhD</last_name>
    <phone>(319) 356-3693</phone>
    <email>bryan-allen@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather Brown, RN, BAN, OCN</last_name>
    <phone>(319) 384-7912</phone>
    <email>heather-brown@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Vollstedt, RN, BSN, OCN</last_name>
      <phone>319-353-7143</phone>
      <email>sandy-vollstedt@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Brown, RN, BAN, OCN</last_name>
      <phone>(319) 384-7912</phone>
      <email>heather-brown@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bryan Allen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 31, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Bryan Allen</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Participants may opt in for individual data sharing; the data of those participants who have opted-in will be shared per plan.</ipd_description>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>After completion and analysis of data</ipd_time_frame>
    <ipd_access_criteria>Interested investigators should contact the study PI. Depending upon the data requested, an IRB application may be necessary.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

